Sentiment, signals, and exit timing for the most volatile sector in equities — built on a sovereign AI stack and pressure-tested by a community of analysts.
Catalyst Ventures is a biotech investment intelligence platform. We exist for a specific kind of investor: the one allocating real capital to European biotech — a sector that combines US-grade scientific complexity with European-grade research fragmentation. Sell-side coverage is thin. Translations are slow. Catalyst timelines are buried in PDFs from agencies in five different languages. The result is a market where serious mispricings hide in plain sight, and only patient, well-instrumented investors can see them.
We focus on two things the rest of the market neglects: sentiment analysis across the full information stack — trial readouts, EMA dockets, journal preprints, broker notes, social chatter — and market exit strategies. Most retail tools flag entries. We score the full life of a thesis, from accumulation through the catalyst window through the post-event drift, so you know when conviction has played out and it's time to step aside.
We do not sell investment advice. We sell the apparatus — the engine, the data, and the consensus — that a serious analyst would build for themselves if they had a team of twelve and a Bloomberg licence.
Every deep dive on Catalyst Ventures is built from three independent data lanes that converge into a single synthesis. Each lane is crawled, normalised, and timestamped on its own schedule. The reasoning stack reads across all three at once — so a sentiment score on a Phase 3 readout is anchored to the trial design, the company's last 10-Q, and the editorial reception in Nature, not just one of them.
Fundamentals from licensed institutional feeds — ownership changes, insider transactions, audited financials, balance-sheet runway — cross-referenced live against SEC EDGAR (10-K, 10-Q, 8-K, Form 144) for US-listed names.
Peer-reviewed publications and regulatory dockets are the leading indicators that don't make headlines. We pull PubMed, Nature, Cell, NEJM alongside EMA, MHRA, and FDA action bulletins — then score the cohort, statistical power, and editorial framing.
ClinicalTrials.gov plus the EU Clinical Trials Register plus sponsor pipeline pages, reconciled against company-issued press releases. Every active programme is timestamped to a catalyst window so a readout is never a surprise.
We do not believe in a single-model future. Reasoning under uncertainty is a team sport — different models have measurably different strengths, and the cost of being wrong in biotech is too high to bet on one provider. Our pipeline is multi-model from the ground up.
The primary reasoning core. Every factual claim in a Catalyst Ventures deep dive is run through Google Search Grounding so it ships with a live, dated citation — not a model-cached approximation. Gemini's long context window lets us reason across an entire 200-page S-1 in a single pass; its multi-modal head lets us read trial-result charts the same way an analyst does.
Where Gemini reads, Claude acts. Opus 4.7 powers the next generation of platform intelligence: autonomous catalyst monitors that wake up when an EMA bulletin lands, multi-step thesis validators that stress-test a Bull Case against three years of comparable readouts, and a conversational research interface that holds a 30-turn dialogue without losing the plot.
A Catalyst Ventures deep dive is not a summary. It is the work product a buy-side analyst would assemble over two days, compressed into the time it takes to read one. Two specific audiences get specific value.
Every report is sourced, scored, and contested — a portfolio-grade research package you can put in front of a partner meeting, a family office, or an LP without rewriting it. Citations land with live URLs; the Bull and Bear cases ship with named community analysts and their historical accuracy. It is, in venture-capital language, defensible diligence on a budget that scales.
We collapse twelve SEC filings, four trial readouts, three preprints, and a fortnight of news cycles into one number: a sentiment score with a confidence band and a catalyst countdown. When that number diverges from price — the platform's core thesis — we flag it. When the thesis plays out, we flag the exit just as clearly.
Free gets you the surface of the platform and enough signal to know if it's for you. Subscription gets you the full apparatus — the institutional feeds, the deep-dive engine, and the priority queue.
The public surface of the platform — designed to be useful on its own, and to give you an unfiltered sense of how the engine reads the market.
The full Catalyst Ventures apparatus. Built for investors who treat biotech as a serious position in their book.
The pieces below are funded, scoped, and either in build or in active rollout to a closed group. Subscribers see them first; we'll backport the surface bits to the free tier where the underlying data permits.
Autonomous catalyst monitoring loops that wake up on dockets and filings, stress-test the existing Bull / Bear cases against historical comparables, and write a fresh recommendation when the signal changes. Powered end-to-end by Claude Opus 4.7's agentic loop.
Targeted deep coverage of the four niches that pay European biotech investors disproportionately: Swiss & Dutch gene-therapy clusters, Scandinavian rare-disease specialists, German / UK digital-health platforms, and French oncology pipelines.
Connect your real book (via brokerage API) and let the engine size, monitor, and alert on every high-volatility position you hold — including catalyst-window draw-down warnings and recommended trim levels at the exit.
The subscription waitlist is open. Email-only, no card, no commitment — we'll send you an invite when access opens.
Catalyst Ventures is a research platform, not an investment advisor. We use advanced technology to aggregate and analyse public and licensed data. All investment decisions should be made based on your own due diligence and in consultation with qualified professionals.